{
    "2018-06-14": [
        [
            {
                "time": "",
                "original_text": "[增持-B评级]复星医药(600196)公司快报：类风关III期临床启动 利妥昔多适应症研发进入尾声",
                "features": {
                    "keywords": [
                        "复星医药",
                        "类风关III期",
                        "临床启动",
                        "利妥昔",
                        "多适应症"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "全国断供的“救命药”赫赛汀，一至两个月将有货！",
                "features": {
                    "keywords": [
                        "救命药",
                        "赫赛汀",
                        "断供",
                        "有货"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业中期策略：聚焦服务、优质医药、商业三条主线(附股)",
                "features": {
                    "keywords": [
                        "医药行业",
                        "中期策略",
                        "服务",
                        "优质医药",
                        "商业"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业投资策略报告：医保支出结构调整支持创新药爆发",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资策略",
                        "医保支出",
                        "创新药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药(600196)：生物药龙头 核心产品收获在即",
                "features": {
                    "keywords": [
                        "复星医药",
                        "生物药",
                        "龙头",
                        "核心产品",
                        "收获"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2023-06-14",
                "original_text": "6月14日券商晨会研报汇编",
                "features": {
                    "keywords": [
                        "券商晨会",
                        "研报汇编"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业:关注优先审评受益标的+商业板块",
                "features": {
                    "keywords": [
                        "医药生物",
                        "优先审评",
                        "受益标的",
                        "商业板块"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}